CORAL GABLES, Fla. — November 24, 2025 — Leads & Copy — Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025, the company announced today. President and CEO Rich Daly, along with other members of Catalyst’s management team, will participate in the conference.
The presentation is scheduled for 12:35pm ET on Monday, December 8, 2025.
A live webcast and replay of the presentation will be available in the Investors section of Catalyst’s website.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. The company focuses on in-licensing, commercializing, and developing innovative therapies, maintaining a well-established U.S. presence as the cornerstone of its commercial strategy while evaluating strategic opportunities to expand its global footprint. Catalyst was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. The company is headquartered in Coral Gables, Fla.
Catalyst prioritizes accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. The company has a proven track record of bringing life-changing treatments to the market.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties. Refer to Catalyst’s Annual Report on Form 10-K for the fiscal year 2024 and subsequent SEC filings for factors that could adversely affect Catalyst. Catalyst undertakes no obligation to update this information.
Investor Contact: Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com
Media Contact: David Schull or Olipriya Das, Russo Partners (858) 717-2310, 646 942 5588 david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com
Source: Catalyst Pharmaceuticals, Inc.
